Clinical Investigation of C-Terminal Cross-Linking Telopeptide Test in Prevention and Management of Bisphosphonate-Associated Osteonecrosis of the Jaws

Journal of Oral and Maxillofacial Surgery

Volumn 67, Issue 6, 2009, Pages 1167-1173

  Kunchur, Ranjit ^a   Need, Allan ^b   Hughes, Toby ^a   Goss, Alastair ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGE DETERMINATION; AGED; ARTICLE; BONE DISEASE; C TERMINAL CROSS LINKING TELOPEPTIDE TEST; CLINICAL TRIAL; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DRUG WITHDRAWAL; FEMALE; HUMAN; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE MYELOMA; OSTEOPOROSIS; PAGET BONE DISEASE; PROSTATE METASTASIS; RISK FACTOR; SEX DETERMINATION; TOOTH EXTRACTION; TREATMENT DURATION;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; AGED, 80 AND OVER; ALENDRONATE; BIOLOGICAL MARKERS; BONE DENSITY CONSERVATION AGENTS; CHRONIC DISEASE; COLLAGEN TYPE I; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INJECTIONS, INTRAVENOUS; JAW DISEASES; MALE; MIDDLE AGED; OSTEONECROSIS; OSTEOPOROSIS; PEPTIDES; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEX FACTORS; TOOTH EXTRACTION;

EID: 65549159953     PISSN: 02782391     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joms.2009.02.004     Document Type: Article

References (25)

1. Wang J., Goodger N.M., and Pogrel M.A. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61 (2003) 1104
2. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115
3. Migliorati C.A. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21 (2003) 4253
4. Carter G., and Goss A.N. Letters to the editor: Bisphosphonates and avascular necrosis of the jaws. Aust Dent J 48 (2003) 268
5. Ruggiero S.L., Mehrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527
6. Marx R.E., Sawatari Y., Fortin M., et al. Bisphosphonate induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg 63 (2005) 1567
7. Cheng A., Mavrokokki A., Carter G., et al. The dental implications of bisphosphonates and bone disease. Aust Dent J 50 (2005) S4 (Medications in Dentistry suppl 2)
8. Expert Panel Recommendations. Dental management of patients receiving oral bisphosphonate therapy. J Am Dent Assoc 137 (2006) 1144
9. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate related osteonecrosis of the jaws. J Oral Maxillofac Surg 65 (2007) 369
10. Sambrook P., Olver I., and Goss A.N. Bisphosphonates and osteonecrosis of the jaw: Position statement on behalf of the Australian and New Zealand Bone Mineral Society, Osteoporosis Australia, Medical Oncology Group of Australia and the Australian Dental Society. Aust Fam Physician 35 (2006) 801
11. Mavrokokki A., Cheng A., Stein B., et al. The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65 (2007) 415
12. Need A: Controlling osteoporosis. INVS Newsletter 61, 2006
13. Need A: Serum β CrossLaps-A bone resorption marker. IMVS Newsletter 64, 2007
14. Rosen H.N., Moses A.C., and Garber J. Serum CTX: A new marker of bone resorption that shows treatment effects more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy. Calcific Tissue Int 66 (2000) 100
15. Marx R.E. Oral and Intravenous Bisphosphonate-Induced Osteonecrosis of the Jaws: History, Etiology, Prevention and Treatment (2007), Quintessence Publishing, Hanover Park, IL
16. Marx R.E., Cillo J.E., and Ulloa J.J. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention and treatment. J Oral Maxillofac Surg 65 (2007) 2397
17. Oral and Dental Expert Group. Therapeutic Guidelines Oral and Dental Therapeutic Guidelines (Melbourne) with the Australian Dental Association, Version 1 (2007), Therapeutic Guidelines Limited, West Melbourne, VC, Australia pp 75-79
18. Kunchur R., and Goss A.N. The oral health status of patients on oral bisphosphonates for osteoporosis. Aust Dent J 53 (2008) 354
19. Malmgren B., Aström E., and Söderhäll S. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. J Oral Pathol Med 66.6 (2008) 1320
20. Khosla S., Burr D., Cawley J., et al. Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using CTX testing, prevention and treatment. Letter to the editor. J Oral Maxillofac Surg 66 (2008) 1320
21. Marx R: In reply to Khosla S, Burr D, Cawley J, et al: Letter to the editor. J Oral Maxillofac Surg 66:1321, 2008
22. Dayton L: Doctors angered by ABC report on bone drugs. The Australian December 19, 2007
23. Sambrook P. Bisphosphonate update. Australian Dental Association, Dental Files. Program 3 (2008), Australian Dental Association, St. Leonards, NSW, Autralia
24. Schifter M., Cox S., and Clayden A. The CTX test and bisphosphonate-associated ONJ. ADA News Bulletin 371 (2008) 21
25. National Prescribing Service (Australian). Maintaining bone health to prevent osteoporotic fractures. NPS Bulletin 53, August 2007